Ranbaxy Claims ‘Buyer’s Remorse’ Behind U.S. ANDA Moves
This article was originally published in PharmAsia News
Executive Summary
Suit argues the U.S. FDA granted tentative approvals of generic versions of Valcyte and Nexium to maintain Ranbaxy’s marketing exclusivity.